Table of Content

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency And Limitations
1.4. Key stakeholders

2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the study

3. Executive Summary

4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Advantages of Multiplex Assays over Singleplex Assays Leading to Their Increased Adoption
4.2.1.2. Growing Use of Multiplexing in Companion Diagnostics Driving the Demand for Multiplex Assays
4.2.1.3. High Costs of Multiplex Assay Equipment Hampering Adoption Among End Users
4.2.1.4. Increasing Focus on Personalized Medicine Boosting the Utilization of Multiplex Assays
4.2.1.5. Shortage of Skilled Professionals and the Risk of Cross-reactivity Limiting the Adoption of Multiplex Assays
4.2.2. Factor Analysis
4.3. Technology Trends
4.3.1. Technological Advancements in Multiplex PCR Technology
4.3.2. Integration of Artificial Intelligence and Machine Learning into Multiplex Assay Systems
4.3.3. Development of Smartphone-based Diagnostic Testing Platforms
4.4. Regulatory Analysis
4.4.1. North America
4.4.1.1. U.S.
4.4.1.2. Canada
4.4.2. Europe
4.4.3. Asia-Pacific
4.4.3.1. China
4.4.3.2. India
4.4.3.3. Japan
4.4.3.4. South Korea
4.4.4. Latin America
4.4.5. Middle East & Africa
4.5. Pricing Analysis
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Suppliers
4.6.2. Bargaining Power of Buyers
4.6.3. Threat of Substitutes
4.6.4. Threat of New Entrants
4.6.5. Degree of Competition

5. Multiplex Assays Market Assessment?by Type
5.1. Overview
5.2. Protein Multiplex Assays
5.2.1. Bead-based Assays
5.2.2. Planar Assays
5.3. Nucleic Acid Multiplex Assays
5.4. Cell-based Multiplex Assays

6. Multiplex Assays Market Assessment? by Product
6.1. Overview
6.2. Consumables
6.3. Instruments
6.4. Software & Services

7. Multiplex Assays Market Assessment? by Technology
7.1. Overview
7.2. Flow Cytometry
7.3. Multiplex Immunoassay
7.4. Multiplex Real-time PCR
7.5. Sequencing
7.6. Other Technologies

8. Multiplex Assays Market Assessment? by Application
8.1. Overview
8.2. Research & Development
8.3. Clinical Diagnosis
8.3.1. Infectious Diseases
8.3.2. Oncology
8.3.3. Cardiovascular Diseases
8.3.4. Autoimmune Diseases
8.3.5. Other Diseases

9. Multiplex Assays Market Assessment? by End User
9.1. Overview
9.2. Pharmaceutical & Biotechnology Companies
9.3. Diagnostic Laboratories
9.4. Hospitals
9.5. Other End Users

10. Multiplex Assays Market Assessment?by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa

11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies

12. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, and Strategic Developments)
12.1. Seegene, Inc.
12.2. F. Hoffmann-La Roche Ltd.
12.3. Thermo Fisher Scientific, Inc.
12.4. Illumina, Inc.
12.5. QIAGEN N.V.
12.6. Becton, Dickinson and Company
12.7. Bio-Rad Laboratories, Inc.
12.8. DiaSorin S.p.A.
12.9. PerkinElmer, Inc.
12.10. Agilent Technologies, Inc.
12.11. Abbott Laboratories
12.12. Siemens Healthineers AG
12.13. Merck KGaA
12.14. Quanterix Corporation
(Note: SWOT analysis is provided for the top 5 companies)

13. Appendix
13.1. Available Customization
13.2. Related Reports



List of Figures

List of Figures
Figure 1 Market Ecosystem
Figure 2 Key Stakeholders
Figure 3 Research Process
Figure 4 Secondary Sources Referenced for This Study
Figure 5 Primary Research Techniques
Figure 6 Key Executives Interviewed
Figure 7 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 8 Market Sizing and Growth Forecast Approach
Figure 9 Global Multiplex Assays Market, By Type, 2023 Vs. 2030 (USD Million)
Figure 10 Global Multiplex Assays Market, By Product, 2023 Vs. 2030 (USD Million)
Figure 11 Global Multiplex Assays Market, By Technology, 2023 Vs. 2030 (USD Million)
Figure 12 Global Multiplex Assays Market, By Application, 2023 Vs. 2030 (USD Million)
Figure 13 Global Multiplex Assays Market, By End User, 2023 Vs. 2030 (USD Million)
Figure 14 Global Multiplex Assays Market, By Geography
Figure 15 Impact Analysis of Market Dynamics
Figure 16 Pharmaceutical R&D Expenditures in The U.S., Europe, And China, 2010 Vs. 2019 Vs. 2020 (USD Million)
Figure 17 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 18 EU Regulatory Pathway – IVDR 2017/746
Figure 19 Porter’s Five Forces Analysis
Figure 20 Global Multiplex Assays Market, By Type, 2023 Vs. 2030 (USD Million)
Figure 21 Global Multiplex Assays Market, By Product, 2023 Vs. 2030 (USD Million)
Figure 22 Global Multiplex Assays Market, By Technology, 2023 Vs. 2030 (USD Million)
Figure 23 Global Multiplex Assays Market, By Application, 2023 Vs. 2030 (USD Million)
Figure 24 U.S.: New Molecular Entity (NME) Approvals (2011-2023)
Figure 25 Estimated Number of New Cancer Cases (In Million)
Figure 26 Global Multiplex Assays Market, By End User, 2023 Vs. 2030 (USD Million)
Figure 27 Global Pharmaceutical R&D Spending, 2012–2026 (USD Billion)
Figure 28 Global Multiplex Assays Market, By Region, 2023 Vs. 2030 (USD Million)
Figure 29 North America: Number of People Aged 65 Years and Above, 2015–2021 (In Million)
Figure 30 North America: Multiplex Assays Market Snapshot
Figure 31 U.S.: Pharmaceutical R&D Expenditure, 2014–2021 (USD Billion)
Figure 32 Europe: Pharmaceutical Industry R&D Expenditure, 2000–2021 (USD Million)
Figure 33 Europe: Multiplex Assays Market Snapshot
Figure 34 U.K: Estimated Number of Cancer Cases, 2020–2030 (In Million)
Figure 35 U.K.: Number of People Diagnosed with Sexually Transmitted Infections, 2018–2020 (In Thousand)
Figure 36 Pharmaceutical R&D Expenditure, By Country, 2020 (USD Million)
Figure 37 Asia-Pacific: Multiplex Assays Market Snapshot
Figure 38 Latin America: Multiplex Assays Market Snapshot
Figure 39 Key Growth Strategies Adopted by Leading Players, 2020–2023
Figure 40 Multiplex Assays Market: Competitive Benchmarking (Based on Products)
Figure 41 Multiplex Assays Market: Competitive Benchmarking (Based on Geography)
Figure 42 Competitive Dashboard: Multiplex Assays Market
Figure 43 Seegene, Inc.: Financial Overview (2022)
Figure 44 F. Hoffmann-La Roche Ltd: Financial Overview (2022)
Figure 45 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 46 Illumina, Inc.: Financial Overview (2022)
Figure 47 Qiagen N.V.: Financial Overview (2022)
Figure 48 Becton, Dickinson and Company: Financial Overview (2022)
Figure 49 Bio-Rad Laboratories: Financial Overview (2022)
Figure 50 DiaSorin S.p.A.: Financial Overview (2022)
Figure 51 PerkinElmer, Inc.: Financial Overview (2022)
Figure 52 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 53 Abbott Laboratories: Financial Overview (2022)
Figure 54 Siemens Healthineers Ag: Financial Overview (2022)
Figure 55 Merck KGaA.: Financial Overview (2022)
Figure 56 Quanterix Corporation: Financial Overview (2022)